ACH. Arch Biopartners Inc.

Arch Biopartners Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide; Begins Screening Patients in Florida

Arch Biopartners Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide; Begins Screening Patients in Florida
EN
07/10/2020

Underlying

ACH.Arch Biopartners Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Arch Biopartners Inc.

 PRESS RELEASE
Free
ACH. Arch Biopartner...

Arch Biopartners Announces Toronto General Hospital Ethics Board Appro...

Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI) TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network (UHN) Research Ethics Board has granted approval for Toronto General Hospital to participate in the Company’s ongoing for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). With this ethics approval in place a...

April 22, 2025 1 EN
 PRESS RELEASE
Free
ACH. Arch Biopartner...

Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONT...

Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI)Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its unique off-target effects that block toxin uptake into the kidney tissueArch continues to perform a Phase II trial for LSALT peptide targeting cardiac surgery-associated-AKI Drug toxins and CS-AKI account for up to 50% of all AKI occurring in hospitals, for whic...

August 2, 2024 1 EN
 PRESS RELEASE
Free
ACH. Arch Biopartner...

Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Produc...

Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product TORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced that Dalton Pharma Services (Dalton) has completed the good manufacturing practice (GMP) glass vial filling stage for cilastatin, the Company’s second drug candidate for preventing acute kidney injury (AKI). Over the next six to eight weeks Dalton will be completing the quality control process which will culminate with the release of a first-ever, stand-alone cilastatin drug product to be used in a P...

June 27, 2024 1 EN
 PRESS RELEASE
Free
ACH. Arch Biopartner...

Arch Biopartners Announces University of Calgary Ethics Approval to Pr...

Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI) TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University of Calgary’s Conjoint Health Research Ethics Board (CHREB) has approved the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The clinical team at the University of Calgary Cumming School...

June 18, 2024 1 EN
 PRESS RELEASE
Free
ACH. Arch Biopartner...

St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targe...

St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from St. Michael’s Hospital, a site of Unity Health Toronto, has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver....

April 16, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch